Trial Profile
A Pilot, Double-blind, Placebo-controlled, 2-period Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Nov 2016
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Almirall S.A.; AstraZeneca
- 15 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 May 2014 New trial record